Volume 14, Number 1—January 2008
Dispatch
Adamantane-Resistant Influenza Infection During the 2004–05 Season
Table 1
Clinical feature | Adamantane-resistant influenza, n = 72 | Adamantane-susceptible influenza, n = 80 | p value* |
---|---|---|---|
Median duration of illness† | 12 days | 13 days | 0.96 |
No. (%) hospitalized | 7 (10) | 9 (12) | 0.74 |
No. (%) fully recovered at time of follow-up interview | 63 (88) | 65 (81) | 0.29 |
Median no. symptoms‡ | 9 | 8 | 0.59 |
No. (%) receiving antiviral treatment§ | 15 (21) | 31 (39) | 0.02 |
Median time from symptom onset to healthcare encounter | 3 days | 2 days | 0.34 |
Single symptom, no. (%)‡ | |||
Fever | 34 (69) | 52 (74) | 0.56 |
Cough | 48 (98) | 68 (97) | 0.78 |
Headache | 41 (84) | 53 (76) | 0.29 |
Muscle pain | 37 (76) | 45 (64) | 0.57 |
Nasal congestion | 40 (82) | 54 (77) | 0.55 |
Hoarseness | 35 (71) | 55 (79) | 0.37 |
Fatigue | 45 (92) | 66 (94) | 0.72 |
Ear pain | 16 (33) | 24 (34) | 0.85 |
Sore throat | 29 (59) | 40 (57) | 0.82 |
Difficulty breathing | 28 (57) | 35 (50) | 0.44 |
Wheezing | 25 (51) | 42 (60) | 0.33 |
Nausea | 16 (33) | 27 (39) | 0.51 |
Vomiting | 10 (20) | 9 (13) | 0.27 |
Diarrhea | 12 (24) | 15 (21) | 0.70 |
Rash | 2 (4) | 2 (3) | 1.00 |
Combined symptoms, no. (%)‡ | |||
Fever and cough | 33 (67) | 52 (74) | 0.41 |
Fever and headache | 31 (63) | 43 (61) | 0.84 |
Fever, cough, and headache | 30 (61) | 43 (61) | 0.98 |
Fever and muscle pain | 29 (59) | 39 (56) | 0.71 |
Fever, headache, and muscle pain | 27 (55) | 35 (50) | 0.58 |
Fever, headache, muscle pain, and cough | 26 (53) | 35 (50) | 0.74 |
*χ2, Fisher exact, or Wilcoxon rank sum tests performed as appropriate.
†Based on 128 influenza A patients who had recovered fully at the time of follow-up interview.
‡Children 6 to 23 months of age were excluded from the numerator and denominator for symptoms.
§One patient had received antiviral treatment prior to influenza culture.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.